PA
TRIL

Perceptive Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Perceptive Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-114,674
Closed -$1.63M – 156
2020
Q3 		$1.63M Hold
114,674
– – 0.02% 113
2020
Q2 		$928K Buy
+114,674
New +$709K 0.02% 113
2016
Q2 		– Sell
-30,000
Closed -$278K – 213
2016
Q1 		$278K Hold
30,000
– – 0.02% 144
2015
Q4 		$378K Hold
30,000
– – 0.03% 104
2015
Q3 		$391K Hold
30,000
– – 0.03% 113
2015
Q2 		$655K Buy
+30,000
New +$684K 0.04% 128

Other funds holding TRIL

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Perceptive Advisors's TRIL Position: Q4 2020 in Review

Perceptive Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2020, closing a stake of 114,674 shares — an estimated $1.63M sold.

Perceptive Advisors first reported a position in TRIL in Q2 2015 and held it in 6 quarters. The position peaked at $1.63M in Q3 2020. 131 funds tracked by Wall St. Rank hold TRIL as of Q4 2020.

  • Perceptive Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2020 after selling out during the quarter.
  • Perceptive Advisors sold 114,674 Trillium Therapeutics Inc. shares in Q4 2020, an estimated $1.63M.
  • Perceptive Advisors first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 6 quarters.
  • Perceptive Advisors's Trillium Therapeutics Inc. position peaked at $1.63M in Q3 2020.
  • 131 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2020.

Based on Perceptive Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.